Risk of development of visceral metastases subsequent to abiraterone vs placebo: An analysis of mode of radiographic progression in COU-AA-302.
Benjamin A TeplyFang QiuEmmanuel S AntonarakisMichael A CarducciSamuel R DenmeadePublished in: The Prostate (2020)
Abiraterone was not associated with increased risk of visceral metastatic disease at the time of progression compared with placebo.